Search Results - "SAMARA, EMIL"

Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS by Ziemssen, Tjalf, Tumani, Hayrettin, Sehr, Tony, Thomas, Katja, Paul, Friedemann, Richter, Nils, Samara, Emil, Spiegelstein, Ofer, Sorani, Ella, Bar-Ilan, Oren, Mimrod, Dorit, Hayardeny, Liat

“…Laquinimod is an oral immunomodulator in clinical development to treat relapsing-remitting multiple sclerosis (RRMS). Laquinimod is in clinical development for…”
Get full text

Population Pharmacokinetics of Telavancin in Healthy Subjects and Patients with Infections by SAMARA, Emil, SHAW, Jeng-Pyng, BARRIERE, Steven L, WONG, Shekman L, WORBOYS, Philip

“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

In vivo Target Modulation and Biological Activity of CHIR-258, a Multitargeted Growth Factor Receptor Kinase Inhibitor, in Colon Cancer Models by SANG HOON LEE, DE MENEZES, Daniel Lopes, HEISE, Carla, VORA, Jayesh, HARRIS, Alex, YE, Helen, NORDAHL, Lara, GARRETT, Evelyn, SAMARA, Emil, AUKERMAN, Sharon Lea, GELB, Arnold B

“…Purpose: To evaluate the therapeutic and biological effects of CHIR-258, an orally bioavailable, potent inhibitor of class III-V receptor tyrosine kinases, in…”
Get full text

Pharmacokinetics and Pharmacodynamics of Recombinant FGF-2 in a Phase I Trial in Coronary Artery Disease by Bush, Mark A., Samara, Emil, Whitehouse, M. J., Yoshizawa, Carl, Novicki, Deborah L., Pike, Marilyn, Laham, Roger J., Simons, Michael, Chronos, Nicolas A.

“…Fibroblast growth factor‐2 (FGF‐2) is a heparin‐binding protein capable of inducing angiogenesis in multiple animal models of chronic ischemia. The…”
Get full text

Lack of clinically relevant differences in safety and pharmacokinetics after second‐dose administration of intranasal diazepam within 4 h for acute treatment of seizure clusters: A population analysis by Cascino, Gregory D., Tarquinio, Daniel, Wheless, James W., Hogan, Robert Edward, Sperling, Michael R., Desai, Jay, Vazquez, Blanca, Samara, Emil, Misra, Sunita N., Carrazana, Enrique, Rabinowicz, Adrian L.

“…Objective Current diazepam nasal spray labeling requires waiting 4 h before administering a second dose. The objective of the current analyses was to examine…”
Get full text

Dose optimization of novel BRAF inhibitor FORE8394 based on PK and efficacy results by Sherman, Eric Jeffrey, De La Fuente, Macarena Ines, Yaeger, Rona, Tsai, Frank Yung-Chin, Janku, Filip, Butowski, Nicholas A., Allen, Carl E., Ammakkanavar, Natraj Reddy, Taylor, Jennie Webster, Samara, Emil, Mould, Diane R., Michelson, Glenn, Kline, Irina, Paz, Michael, Tussay-Lindenberg, Alexia, Wong, Kongming, Shepherd, Stacie Peacock, Jiang, Ping, Rodon Ahnert, Jordi

“…3106 Background: FORE8394 is a selective inhibitor of class 1 (V600) and 2 (activating non-V600) BRAF alterations that avoids paradoxical MAPK pathway…”
Get full text

TRLS-02. SAFETY AND EFFICACY OF BRAF INHIBITOR PLIXORAFENIB (FORE8394; PLX8394) IN CHILDREN AND ADULTS WITH RECURRENT, BRAF-ALTERED PRIMARY CENTRAL NERVOUS SYSTEM TUMORS (PCNST) by de la Fuente, Macarena, Butowski, Nicholas A, Taylor, Jennie, Yaeger, Rona, Tsai, Frank Y-C, Janku, Filip, Allen, Carl E, Ammakkanavar, Natraj, Michelson, Glenn, Jiang, Ping, Samara, Emil, Paz, Michael, Tussay-Lindenberg, Alexia, Wang, Kongming, Shepherd, Stacie P, Kline, Irina, Sherman, Eric, Rodon, Jordi

Get full text

BL‐8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open‐label safety and efficacy phase 2a study by Borthakur, Gautam, Ofran, Yishai, Tallman, Martin S., Foran, James, Uy, Geoffrey L., DiPersio, John F., Showel, Margaret M., Shimoni, Avichai, Nagler, Arnon, Rowe, Jacob M., Altman, Jessica K., Abraham, Michal, Peled, Amnon, Shaw, Stephen, Bohana‐Kashtan, Osnat, Sorani, Ella, Pereg, Yaron, Foley‐Comer, Adam, Oberkovitz, Galia, Lustig, Tzipi M., Glicko‐Kabir, Irit, Aharon, Arnon, Vainstein‐Haras, Abi, Kadosh, Shaul E., Samara, Emil, Al‐Rawi, Ahmed N., Pemmaraju, Naveen, Bueso‐Ramos, Carlos, Cortes, Jorge E., Andreeff, Michael

“…Background CXCR4 mediates the retention and survival of acute myelogenous leukemia blasts in bone marrow and contributes to their resistance to chemotherapy…”
Get full text

A Phase I, Randomized, SAD, MAD, and PK Study of Risvodetinib in Older Adults and Parkinson’s Disease by Werner, Milton H., Olanow, C. Warren, McGarry, Andrew, Meyer, Christopher, Kruger, Sydney, Klint, Carl, Pellecchia, Jacqueline, Walaker, Shannon, Ereshefsky, Larry, Blob, Lawrence, Hassman, Howard, Rodriguez, Carlos, Samara, Emil, Safirstein, Beth, Ellenbogen, Aaron

“…Background: Pre-clinical studies suggest that c-Abl activation may play an important role in the etiology of Parkinson’s disease, making c-Abl an important…”
Get full text

A Thorough QT/QTc Study With Laquinimod, a Novel Immunomodulator in Development for Multiple Sclerosis and Huntington Disease by Spiegelstein, Ofer, Mimrod, Dorit, Rabinovich, Laura, Eyal, Eli, Sprenger, Craig, Elgart, Anna, Samara, Emil, Morganroth, Joel

“…In this randomized double‐blind study, 4 groups of healthy subjects (50 per arm) participated to evaluate the effect of laquinimod, an oral treatment in…”
Get full text

Predicting Pediatric Age-Matched Weight and Body Mass Index by Sy, Sherwin K. B., Asin-Prieto, Eduardo, Derendorf, Hartmut, Samara, Emil

“…The empirical scaling from adult to pediatric using allometric size adjustments based on body weight continued to be the mainstream method for pediatric dose…”
Get full text

A preliminary evaluation of the relationship of cannabinoid blood concentrations with the analgesic response to vaporized cannabis by Wilsey, Barth L, Deutsch, Reena, Samara, Emil, Marcotte, Thomas D, Barnes, Allan J, Huestis, Marilyn A, Le, Danny

“…A randomized, placebo-controlled crossover trial utilizing vaporized cannabis containing placebo and 6.7% and 2.9% delta-9-tetrahydrocannabinol (THC) was…”
Get full text

Pharmacokinetics of Laquinimod, an Oral Immunomodulatory Agent in Development for The Treatment of Relapsing-Remitting Multiple Sclerosis (P7.237) by Tumani, Hayrettin, Ziemssen, Tjalf, Paul, Friedemann, Marziniak, Martin, Richter, Nils, Heesen, Christoph, Gilgun-Sherki, Yossi, Gorfine, Tali, Spiegelstein, Ofer, Samara, Emil, Sidi, Yulia, Mimrod, Dorit

“…Abstract only…”
Get full text

Pharmacokinetics of dalfampridine extended release 7.5-mg tablets in healthy subjects and individuals with mild and moderate renal impairment: An open-label study by Samara, Emil, Winkle, Peter, Pardo, Patricia, Henney III, Herbert R., Way, Susan L., Brown, Eppie, Lee, Angela, Blight, Andrew R.

“…Dalfampridine extended release tablets (D‐ER; prolonged‐release fampridine in Europe) are available to improve walking in patients with multiple sclerosis…”
Get full text

Fostamatinib, a Syk-Kinase Inhibitor, Does Not Affect Methotrexate Pharmacokinetics in Patients With Rheumatoid Arthritis by Baluom, Muhammad, Samara, Emil, Grossbard, Elliott B., Lau, David T.-W.

“…Fostamatinib (R788) is being investigated as an add‐on therapy for the treatment of rheumatoid arthritis (RA) in patients with inadequate response to…”
Get full text

Characterization of the pharmacokinetics and pharmacodynamics of a new oral thromboxane A2-receptor antagonist AA-2414 in normal subjects: population analysis by Hussein, Z, Samara, E, Locke, C S, Orchard, M A, Ringham, G L, Granneman, G R

“…The pharmacokinetics and pharmacodynamics of AA-2414 [(+-)-7-(3,5,6-trimethyl-1,4-benzoquinon-2-yl)-7-phenylheptano+ ++ ic acid] were evaluated in 39 healthy…”
Get more information

Once-a-day extended-release dosage form of divalproex sodium III: development and validation of a Level A in vitro-in vivo correlation (IVIVC) by Dutta, Sandeep, Qiu, Yihong, Samara, Emil, Cao, Guoliang, Granneman, G Richard

“…Defining a quantitative and reliable relationship between in vitro drug release and in vivo absorption is highly desired for rational development,…”
Get more information

Controlled release of recombinant insulin-like growth factor from a novel formulation of polylactide-co-glycolide microparticles by Singh, Manmohan, Shirley, Bret, Bajwa, Kamal, Samara, Emil, Hora, Maninder, O’Hagan, Derek

“…The purpose of the current study was to develop a controlled-release delivery system for recombinant insulin-like growth factor (rhIGF-I)…”
Get full text

Comparison of Pharmacokinetics and Pharmacodynamics of two different dosing regimens of Proleukin® (IL-2) in Combination with rituximab: The effect of NK cell expansion by Milan, Sandra, Hurst, Deborah, Michelson, Glenn, Samara, Emil

“…Background: Published results from studies testing two different dosing regimens of IL-2 in combination with rituximab have shown that thrice-weekly dosing of…”
Get full text

Role of population pharmacokinetics in Drug development : A pharmaceutical industry perspective by SAMARA, E, GRANNEMAN, R

“…Population pharmacokinetic analysis is a relatively new approach which can be used to obtain important pharmacokinetic and pharmacodynamic information from…”
Get full text